The mean age of our series was 70,7
years (SD 5,2 years). Gleason was 6 (3 + 3) in 53,3%, Gleason 7 (3 + 4) in
24,4%, Gleason 7 (4 + 3) in 11,2%, Gleason 8 (3 + 5) in 2,2%, Gleason 8 (4 + 4)
in 6,7% and Gleason 9 (4 + 5) in 2,2%. Very
low risk were 2,2%, 33,3% low risk, 22,2% favorable intermediate
risk, 24,4% unfavorable intermediate risk, 11,1% high risk and 6,7% very high
risk.
Treatment was scheduled in
5 sessions of 7,25 Gy with a total doses of 36,25 Gy. Overall,
42,2% received concurrent androgen deprivation therapy (ADT).
Median PSA
pre-treatment in our
series was 7,9 ng/ml (IR 6.5-12.4 ng/ml). After a median
follow-up of 15.0 months (IR 11.5-17.0 months), PSA nadir was achieved with a
median level of
0,45 ng/ml (0,03-1,50 ng/ml).
Considering men treated by SBRT with the addition of ADT, the
median PSA at diagnosis was 8,1 ng/ml (IR 6,6-13,8 ng/ml) while the median PSA
nadir during this follow-up was 0,01 ng/ml (IR 0,01-0,14 ng/ml). Analyzing
patients who did not receive concurrent ADT, their median PSA at diagnosis was
7,8 ng/ml (IR 6,5-1,0 ng/ml), with a median PSA-nadir of 1,1 ng/ml (IR 0,6-2,1
ng/ml).
During our study
we observed neither PSA bounce nor biochemical recurrence.
PSA nadir <0,3 ng/ml was achieved in 40,0%
of our serie; 55,6%
nadir <0,5 and 68,9% <1,0 ng/ml.
Assessing the
absence or presence of ADT, patients who received exclusively SBRT 57,8%
(n = 26), the PSA nadir was <0,3 ng/ml in 3,8%; <0,5 ng/ml in 23,1% and
<1,0 ng/ml in 46,2% of patients. In these patients, the mean time from SBRT
to nadir was 10,4 months (SD 4,7 months) and a median of 10,5 months (IR
7,0-13,0 months). Patients treated with ADT concomitant
to SBRT 24,2% (n = 19), the PSA-nadir was <0,3 in 89,5% and <0,5 in 100%
of the patients.